he US Pharma and Biotech Summit 2026, organized by FT Live in collaboration with Endpoints News, brings together top executives, investors, and experts to share insights about the future of life sciences in America and worldwide. The event addresses challenges in drug development, policy, regulation, and investment, offering in-person and digital experience…
— and 27 more, by name unsung —
The pre-Covid consensus around vaccines and many long-held public health priorities has been shattered. Government authorities, healthcare companies and experts are being forced to…
The sky-high demand for weight loss drugs has provided momentum to start-ups offering products directly to consumers, pushed big pharma companies to create their own consumer acces…
The 1975 Asilomar Conference on Recombinant DNA marked the start of the modern biotechnology era. Half a century later, medicine has been transformed by biotech breakthroughs. Now,…
Biopharma dealmaking is showing signs of renewed momentum, with factors such as the looming patent cliff helping to drive targeted M&A activity. Increasing the volume of larger acq…
Consumer technology is bleeding into healthcare. Wearable devices that monitor biometrics and apps that claim to treat and track health conditions are growing in popularity. But he…
Business processes are evolving as new tools and technologies make seamless integration across departments more achievable. Yet overcoming structural barriers and fragmented workfl…
Longevity medicine is a big umbrella with growing demand for innovation. Investing in efforts to live longer could mean cutting-edge cellular rejuvenation, microdosing GLP-1s, or e…
An audience of 44 companies, parsed from the program.
The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.
67% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.
Of 49 on the bill · classified by free-text title